122 related articles for article (PubMed ID: 35104793)
1. Immunoregulatory effects of glioma-associated stem cells on the glioblastoma peritumoral microenvironment: a differential PD-L1 expression from core to periphery?
Menna G; Manini I; Cesselli D; Skrap M; Olivi A; Ius T; Della Pepa GM
Neurosurg Focus; 2022 Feb; 52(2):E4. PubMed ID: 35104793
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneity Matters: Different Regions of Glioblastoma Are Characterized by Distinctive Tumor-Supporting Pathways.
Manini I; Caponnetto F; Dalla E; Ius T; Della Pepa GM; Pegolo E; Bartolini A; La Rocca G; Menna G; Di Loreto C; Olivi A; Skrap M; Sabatino G; Cesselli D
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066172
[TBL] [Abstract][Full Text] [Related]
3. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
4. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
5. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
7. Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors.
Chen D; Li G; Ji C; Lu Q; Qi Y; Tang C; Xiong J; Hu J; Yasar FBA; Zhang Y; Hoon DSB; Yao Y; Zhou L
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457124
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma.
Wang XP; Guo W; Chen YF; Hong C; Ji J; Zhang XY; Dong YF; Sun XL
Int Immunopharmacol; 2024 May; 133():112074. PubMed ID: 38615383
[TBL] [Abstract][Full Text] [Related]
9. Current advances in PD-1/PD-L1 axis-related tumour-infiltrating immune cells and therapeutic regimens in glioblastoma.
Shu C; Li Q
Crit Rev Oncol Hematol; 2020 Jul; 151():102965. PubMed ID: 32442903
[TBL] [Abstract][Full Text] [Related]
10. Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties.
Clavreul A; Guette C; Faguer R; Tétaud C; Boissard A; Lemaire L; Rousseau A; Avril T; Henry C; Coqueret O; Menei P
J Pathol; 2014 May; 233(1):74-88. PubMed ID: 24481573
[TBL] [Abstract][Full Text] [Related]
11. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
12. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
[TBL] [Abstract][Full Text] [Related]
13. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma.
Tong L; Li J; Li Q; Wang X; Medikonda R; Zhao T; Li T; Ma H; Yi L; Liu P; Xie Y; Choi J; Yu S; Lin Y; Dong J; Huang Q; Jin X; Lim M; Yang X
Theranostics; 2020; 10(13):5943-5956. PubMed ID: 32483429
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma.
Zhang P; Miska J; Lee-Chang C; Rashidi A; Panek WK; An S; Zannikou M; Lopez-Rosas A; Han Y; Xiao T; Pituch KC; Kanojia D; Balyasnikova IV; Lesniak MS
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23714-23723. PubMed ID: 31712430
[TBL] [Abstract][Full Text] [Related]
15. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
16. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.
Berghoff AS; Kiesel B; Widhalm G; Rajky O; Ricken G; Wöhrer A; Dieckmann K; Filipits M; Brandstetter A; Weller M; Kurscheid S; Hegi ME; Zielinski CC; Marosi C; Hainfellner JA; Preusser M; Wick W
Neuro Oncol; 2015 Aug; 17(8):1064-75. PubMed ID: 25355681
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of programmed cell death ligand 1 expression reveals increased levels in high-grade glioma.
Hölzl D; Hutarew G; Zellinger B; Schlicker HU; Schwartz C; Winkler PA; Sotlar K; Kraus TFJ
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2271-2280. PubMed ID: 33963441
[TBL] [Abstract][Full Text] [Related]
18. Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.
Miyazaki T; Ishikawa E; Matsuda M; Akutsu H; Osuka S; Sakamoto N; Takano S; Yamamoto T; Tsuboi K; Matsumura A
J Neurooncol; 2017 Jun; 133(2):277-285. PubMed ID: 28447277
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma.
Lee KS; Lee K; Yun S; Moon S; Park Y; Han JH; Kim CY; Lee HS; Choe G
J Neurooncol; 2018 Feb; 136(3):453-461. PubMed ID: 29147863
[TBL] [Abstract][Full Text] [Related]
20. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA).
Almuhaisen G; Alhalaseh Y; Mansour R; Abu-Shanab A; Al-Ghnimat S; Al-Hussaini M
Brain Tumor Pathol; 2021 Jan; 38(1):14-22. PubMed ID: 32897465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
